Business Context and Reporting Period
Company: Relmada Therapeutics, Inc. (RLMD)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Relmada is a clinical-stage biotechnology company that recently pivoted its strategy following a comprehensive review. The company terminated its Esmethadone (REL-1017) and Psilocybin (REL-P11) programs in 2025. It has shifted focus to two new assets: NDV-01 (a novel intravesical formulation for bladder cancer, in-licensed from Trigone) and Sepranolone (a neurosteroid for Prader-Willi and Tourette Syndromes, acquired from Asarina). The company is currently listed on the Nasdaq Capital Market following a transfer due to minimum bid price non-compliance.
Key Financial Metrics
| Metric (Six Months Ended June 30, 2025) | Value |
|---|---|
| Revenue | $0 (No commercial products) |
| Net Loss | $(27,425,907) |
| Loss Per Share (Basic & Diluted) | $(0.86) |
| Total Operating Expenses | $28,439,742 |
| Research & Development Expenses | $14,770,400 |
| General & Administrative Expenses | $13,669,342 |
| Cash and Cash Equivalents (June 30, 2025) | $1,353,351 |
| Short-term Investments (June 30, 2025) | $19,266,190 |
| Total Liquidity | $20,619,541 |
| Net Cash Used in Operating Activities | $(24,468,909) |
| Accumulated Deficit | $(668,307,942) |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately $13.4 million compared to the six months ended June 30, 2024. This was driven primarily by the wind-down of the REL-1017 clinical studies and a significant reduction in stock-based compensation expenses.
- Strategic Acquisitions: The company incurred significant upfront costs in Q1 2025 to acquire Sepranolone ($2.76 million cash) and license NDV-01 ($3.5 million cash plus 3.0 million shares of common stock).
- Investment Portfolio: Short-term investments decreased from $41.1 million to $19.3 million as the company liquidated assets to fund operations and acquisitions.
- Stock-Based Compensation: Total stock-based compensation dropped from $15.5 million in the prior year period to $7.9 million, reflecting changes in equity grant activity and the termination of certain programs.
Outlook, Risks, and Management Commentary
Going Concern Warning
Management has raised substantial doubt about the company's ability to continue as a going concern. With a cash burn rate of approximately $24.5 million over six months, current liquidity ($20.6 million) is projected to be insufficient to sustain operations for one year following the report date. Management is evaluating financing strategies, including equity or debt sales, but has not finalized plans.
Strategic Outlook
- NDV-01: Positive 6-month follow-up data from the Phase 2 study was announced in August 2025, showing a 90% complete response rate. The company anticipates 9-month data in H2 2025 and US IND clearance in H1 2026.
- Sepranolone: The company plans to initiate a clinical trial for Prader-Willi Syndrome in H1 2026.
Risks and Contingencies
- Nasdaq Compliance: The company received a 180-day extension (until January 19, 2026) to regain compliance with the $1.00 minimum bid price requirement.
- Future Milestone Obligations: The NDV-01 license agreement includes potential milestone payments of up to $200 million and a 3% royalty on net sales.
- Program Termination: The Esmethadone and Psilocybin programs were terminated in 2025, eliminating future revenue potential from these assets but reducing ongoing burn.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline for securing additional capital given the explicit "substantial doubt" disclosure and current cash burn rate.
- Nasdaq Listing Status: Monitor the stock price to ensure it meets the $1.00 minimum bid requirement for 10 consecutive days before the January 2026 deadline.
- NDV-01 Data Readout: Confirm the release and specifics of the 9-month Phase 2 data expected in the second half of 2025.
- Dilution Risk: Assess the impact of potential equity raises on existing shareholders, noting the company issued 3 million shares for the NDV-01 license in Q1.
- Stock-Based Compensation: Review the $11.2 million in unrecognized stock-based compensation expense related to unvested options, which will impact future earnings.